| Secondary |
| Drug Use For Unknown Indication |
32.9% |
| Antibiotic Therapy |
11.0% |
| Sedation |
11.0% |
| Product Used For Unknown Indication |
10.3% |
| Cardiac Disorder |
8.2% |
| Blood Pressure Management |
5.5% |
| Diuretic Therapy |
5.5% |
| Anaesthesia Procedure |
2.7% |
| Gastritis |
2.7% |
| Muscle Relaxant Therapy |
2.7% |
| Heart Transplant |
2.1% |
| Pulmonary Arterial Hypertension |
2.1% |
| Cardiovascular Disorder |
1.4% |
| Essential Hypertension |
0.7% |
| Gastric Cancer |
0.7% |
| Thrombosis Prophylaxis |
0.7% |
|
| Toxic Epidermal Necrolysis |
31.6% |
| Dermatitis Exfoliative Generalised |
15.8% |
| Syncope |
15.8% |
| Abdominal Pain |
5.3% |
| Dermatitis Exfoliative |
5.3% |
| Drug Interaction |
5.3% |
| Gastric Cancer |
5.3% |
| Renal Impairment |
5.3% |
| Respiratory Arrest |
5.3% |
| Ventricular Tachycardia |
5.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
41.6% |
| Prophylaxis |
9.4% |
| Drug Use For Unknown Indication |
7.3% |
| Hypertension |
6.5% |
| Rheumatoid Arthritis |
4.6% |
| Cardiomyopathy |
3.1% |
| Congestive Cardiomyopathy |
2.9% |
| Atrial Fibrillation |
2.7% |
| Hepatic Neoplasm Malignant |
2.7% |
| Premedication |
2.4% |
| Cardiac Failure |
2.0% |
| Hiv Infection |
2.0% |
| Acute Graft Versus Host Disease |
1.9% |
| Thrombosis Prophylaxis |
1.9% |
| Gastritis |
1.7% |
| Ascites |
1.5% |
| Bone Marrow Conditioning Regimen |
1.5% |
| Klebsiella Infection |
1.5% |
| Abdominal Pain Upper |
1.4% |
| Neoplasm |
1.4% |
|
| Hepatic Encephalopathy |
13.5% |
| Respiratory Failure |
8.1% |
| Aplasia Pure Red Cell |
6.8% |
| Stevens-johnson Syndrome |
6.8% |
| Pulmonary Fibrosis |
5.4% |
| Pyrexia |
5.4% |
| Diarrhoea |
4.1% |
| Electrocardiogram Qt Prolonged |
4.1% |
| Erythema |
4.1% |
| International Normalised Ratio Increased |
4.1% |
| Megacolon |
4.1% |
| Oedema Peripheral |
4.1% |
| Pharyngeal Haemorrhage |
4.1% |
| Platelet Count Decreased |
4.1% |
| Pneumonia |
4.1% |
| Somnolence |
4.1% |
| Thrombocytopenia |
4.1% |
| Thrombotic Microangiopathy |
4.1% |
| Atrioventricular Block Second Degree |
2.7% |
| Cardiac Failure |
2.7% |
|
| Interacting |
| Product Used For Unknown Indication |
66.7% |
| Hypokalaemia |
22.2% |
| Anticoagulant Therapy |
11.1% |
|
| Drug Interaction |
50.0% |
| Haematoma |
25.0% |
| International Normalised Ratio Increased |
25.0% |
|
